Myelofibrosis epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
(→Gender) |
(→Gender) |
||
| Line 17: | Line 17: | ||
===Gender=== | ===Gender=== | ||
*Gender distribution can differ by the subtype, | *Gender distribution can differ by the subtype of the disease with primary myelofibrosis being more prevalent in males and post-essential thrombocythemia being more common in females.<ref name="pmid27540137">{{cite journal |vauthors=Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA |title=Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group |journal=Haematologica |volume=102 |issue=1 |pages=85–93 |date=January 2017 |pmid=27540137 |pmc=5210236 |doi=10.3324/haematol.2016.149559 |url=}}</ref> | ||
Males are more commonly affected with myelofibrosis than females | *Males are more commonly affected with myelofibrosis than females with a male to female ratio of approximately 1.5 to 1.<ref name="pmid22212965">{{cite journal| author=Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R et al.| title=One thousand patients with primary myelofibrosis: the mayo clinic experience. | journal=Mayo Clin Proc | year= 2012 | volume= 87 | issue= 1 | pages= 25-33 | pmid=22212965 | doi=10.1016/j.mayocp.2011.11.001 | pmc=PMC3538387 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22212965 }} </ref> | ||
===Race=== | ===Race=== | ||
Revision as of 14:28, 16 November 2018
|
Myelofibrosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Myelofibrosis epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Myelofibrosis epidemiology and demographics |
|
Risk calculators and risk factors for Myelofibrosis epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
The prevalence of myelofibrosis is approximately 1 per 100,000 individuals worldwide. Myelofibrosis is a disease that tends to affect the middle-aged and elderly population. The mean age at diagnosis is 60 years.[1] Males are more commonly affected with myelofibrosis than females. The male to female ratio is approximately 1.5 to 1.[2] Myelofibrosis usually affects individuals of the Ashkenazi Jews race. African American, Latin American, and Asian individuals are less likely to develop myelofibrosis.[3]
Epidemiology and Demographics
Prevalence
- The prevalence of myelofibrosis is approximately 1 per 100,000 individuals worldwide.[1]
- In developed countries, the prevalence of myelofibrosis is ranged from 0.5 per 100,000 per year to 9 per 100,000 per year.[4]
Incidence
- In developed countries, the incidence of myelofibrosis ranges from a low of 0.3 per 100,000 persons to a high of 1.9 per 100,000 persons with an average incidence of 1.1 per 100,000 persons.[4]
Age
Myelofibrosis is a disease that tends to affect the middle-aged and elderly population. The mean age at diagnosis is 60 years.[1][5]
Gender
- Gender distribution can differ by the subtype of the disease with primary myelofibrosis being more prevalent in males and post-essential thrombocythemia being more common in females.[6]
- Males are more commonly affected with myelofibrosis than females with a male to female ratio of approximately 1.5 to 1.[2]
Race
Myelofibrosis usually affects individuals of the Ashkenazi Jews race. African American, Latin American, and Asian individuals are less likely to develop myelofibrosis.[3]
References
- ↑ 1.0 1.1 1.2 Epidemiology of myelofibrosis. Dr Henry Knipe and Dr Yuranga Weerakkody et al. Radiopaedia 2016. http://radiopaedia.org/articles/myelofibrosis. Accessed on March 8, 2016
- ↑ 2.0 2.1 Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R; et al. (2012). "One thousand patients with primary myelofibrosis: the mayo clinic experience". Mayo Clin Proc. 87 (1): 25–33. doi:10.1016/j.mayocp.2011.11.001. PMC 3538387. PMID 22212965.
- ↑ 3.0 3.1 Causes. The physician's guide to myelofibrosis 2016. http://nordphysicianguides.org/wp-content/uploads/2012/11/NORD_Physician_Guide_to_Myelofibrosis.pdf. Accessed on March 14, 2016
- ↑ 4.0 4.1 Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA (April 2014). "Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union". Eur. J. Haematol. 92 (4): 289–97. doi:10.1111/ejh.12256. PMID 24372927.
- ↑ Cloran F, Banks KP (March 2007). "AJR teaching file: Diffuse osteosclerosis with hepatosplenomegaly". AJR Am J Roentgenol. 188 (3 Suppl): S18–20. doi:10.2214/AJR.05.2141. PMID 17312082.
- ↑ Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA (January 2017). "Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group". Haematologica. 102 (1): 85–93. doi:10.3324/haematol.2016.149559. PMC 5210236. PMID 27540137.